Docebo (DCBO) EBITDA (2019 - 2026)

Docebo (DCBO) has reported EBITDA for 8 consecutive years, with -$1.5 million the latest figure, recorded in Q1 2026.

• Quarterly EBITDA fell 187.41% year-over-year to -$1.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $83.6 million (up 345.51% YoY) and the FY2025 annual result came in at $23.2 million, up 9.13% from the prior year.
• EBITDA slipped to -$1.5 million in Q1 2026 per DCBO's latest filing, from $29.7 million in the prior quarter.
• Over the last five years, EBITDA for DCBO reached as high as $29.7 million in Q4 2025 and fell as low as -$7.5 million in Q2 2023.
• A 5-year average of $6.8 million and a median of $4.2 million in 2024 frame the typical range for EBITDA.
• Annual changes were most pronounced in 2023 — EBITDA slumped 457.0% — and 2024, when it jumped 1224.2%.
• Year by year, EBITDA stood at $2.3 million in 2022, then surged by 187.61% to $6.5 million in 2023, then grew by 20.38% to $7.8 million in 2024, then surged by 279.55% to $29.7 million in 2025, then tumbled by 105.03% to -$1.5 million in 2026.
• According to Business Quant data, EBITDA over the past three periods registered -$1.5 million, $29.7 million, and $27.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.